Parkinson's disease. Incl.: Hemiparkinsonism Paralysis agitans or Parkinsonism
Conditions
Interventions
Intervention 1: In the intervention group, the drug Livergol (silymarin) at a dose of 140 mg three times a day for three months. Intervention 2: In the control group placebo will be given in the same
Treatment - Drugs
Placebo
In the intervention group, the drug Livergol (silymarin) at a dose of 140 mg three times a day for three months.
In the control group placebo will be given in the same shape of studied drug(silymarine)
Sponsors
Vice chancellor for research, Urmia University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age of at least 50 years; At least 6 months have passed since their diagnosis; Treated with anti-Parkinson drugs; Have not other neurological diseases (Alzheimer's, CVA history, etc.) Exclusion criteria: Hospitalization; Surgery; Allergy to Silymarin or drug related reactions.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Movement disorders. Timepoint: monthly. Method of measurement: Modified Hoehn and Yahr Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Life quality. Timepoint: monthly. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hamdolah Sharifi
Urmia University of Medical Sciences
Outcome results
None listed